X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1133) 1133
Publication (104) 104
Book Review (25) 25
Book Chapter (9) 9
Book / eBook (6) 6
Conference Proceeding (2) 2
Dissertation (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (780) 780
oncology (716) 716
female (712) 712
index medicus (666) 666
ovarian cancer (573) 573
chemotherapy (427) 427
ovarian neoplasms - drug therapy (408) 408
cancer (398) 398
middle aged (341) 341
adult (299) 299
aged (294) 294
recurrent (293) 293
obstetrics & gynecology (280) 280
carcinoma (253) 253
recurrent epithelial ovarian (235) 235
ovarian neoplasms - pathology (229) 229
paclitaxel (201) 201
bevacizumab (195) 195
pegylated liposomal doxorubicin (184) 184
antineoplastic combined chemotherapy protocols - therapeutic use (182) 182
care and treatment (179) 179
research (168) 168
phase-ii trial (167) 167
recurrent ovarian cancer (165) 165
treatment outcome (146) 146
gynecologic-oncology-group (141) 141
neoplasm recurrence, local - drug therapy (139) 139
survival (131) 131
antineoplastic agents - therapeutic use (130) 130
disease-free survival (130) 130
epithelial ovarian (128) 128
health aspects (128) 128
carcinoma, ovarian epithelial (124) 124
cisplatin (124) 124
carboplatin (123) 123
aged, 80 and over (122) 122
hematology, oncology and palliative medicine (122) 122
primary peritoneal (118) 118
phase-ii (117) 117
prognosis (116) 116
trial (116) 116
therapy (112) 112
neoplasms, glandular and epithelial - drug therapy (109) 109
ovarian neoplasms - mortality (109) 109
retrospective studies (107) 107
open-label (104) 104
animals (102) 102
fallopian-tube (102) 102
phase-iii trial (102) 102
pharmacology & pharmacy (101) 101
clinical trials (99) 99
obstetrics and gynecology (99) 99
tumors (94) 94
recurrent ovarian (92) 92
drug resistance, neoplasm (91) 91
neoplasm staging (89) 89
relapse (89) 89
surgery (88) 88
ovarian neoplasms - surgery (87) 87
antineoplastic combined chemotherapy protocols - adverse effects (86) 86
angiogenesis (84) 84
cancer therapies (83) 83
endothelial growth-factor (83) 83
analysis (81) 81
angiogenesis inhibitors - therapeutic use (80) 80
ovarian neoplasms - therapy (80) 80
medicine & public health (79) 79
topotecan (79) 79
double-blind (77) 77
drug therapy (77) 77
survival rate (76) 76
carboplatin - administration & dosage (74) 74
platinum (72) 72
metastasis (71) 71
paclitaxel - administration & dosage (69) 69
review (69) 69
genetic aspects (67) 67
neoplasms, glandular and epithelial - pathology (67) 67
platinum-resistant (67) 67
secondary cytoreductive surgery (67) 67
neoplasm recurrence, local - pathology (66) 66
development and progression (65) 65
expression (65) 65
antineoplastic agents (64) 64
diseases (64) 64
article (62) 62
oncology, experimental (62) 62
antimitotic agents (60) 60
antineoplastic agents - administration & dosage (60) 60
breast-cancer (60) 60
cytoreductive surgery (60) 60
mutation (60) 60
patients (60) 60
ovarian neoplasms - metabolism (58) 58
survival analysis (58) 58
ovarian neoplasms - genetics (57) 57
vascular endothelial growth factor (57) 57
medical research (56) 56
primary peritoneal cancer (56) 56
primary peritoneal carcinoma (56) 56
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1114) 1114
German (10) 10
French (9) 9
Korean (8) 8
Polish (2) 2
Spanish (2) 2
Hungarian (1) 1
Italian (1) 1
Japanese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 01/2011, Volume 9, Issue 1, pp. 82 - 113
Journal Article
Journal Article
Critical Reviews in Oncology and Hematology, ISSN 1040-8428, 2010, Volume 79, Issue 1, pp. 17 - 23
Abstract Ovarian cancer remains the leading cause of gynecological cancer-related mortality in the Western World despite the advances in surgical techniques... 
Hematology, Oncology and Palliative Medicine | Targeted therapy | Treatment strategies | Ovarian cancer | GYNECOLOGIC-ONCOLOGY-GROUP | PLATINUM-RESISTANT OVARIAN | BEVACIZUMAB | FALLOPIAN-TUBE CANCER | RECURRENT OVARIAN | PHASE-II TRIAL | ONCOLOGY | PRIMARY PERITONEAL CARCINOMA | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | IMATINIB MESYLATE | ENDOTHELIAL GROWTH-FACTOR | TOR Serine-Threonine Kinases - metabolism | Neoplasms, Glandular and Epithelial - blood supply | Humans | Ovarian Neoplasms - pathology | Neoplasms, Glandular and Epithelial - metabolism | Phosphatidylinositol 3-Kinases - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | TOR Serine-Threonine Kinases - antagonists & inhibitors | PTEN Phosphohydrolase - antagonists & inhibitors | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - blood supply | Proto-Oncogene Proteins c-akt - metabolism | Ovarian Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - pathology | Angiogenesis Inhibitors - pharmacology | PTEN Phosphohydrolase - metabolism | Neovascularization, Pathologic - drug therapy | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Neovascularization, Pathologic - metabolism | Proto-Oncogene Proteins c-akt - antagonists & inhibitors
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2010, Volume 46, Issue 9, pp. 1573 - 1579
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 4/2013, Volume 20, Issue 4, pp. 1348 - 1354
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2014, Volume 136, Issue 3, pp. 498 - 504
Abstract Objective This study aimed to evaluate the prognostic value of quantitative metabolic parameters measured on F-18 FDG PET/CT (FDG PET/CT) at the time... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Relapsed epithelial ovarian cancer | Whole-body total lesion glycolysis | Prognosis prediction | F-18 FDG PET/CT | Whole-body metabolic tumor volume | CRITERIA | RECIST | SOLID TUMORS | SECONDARY CYTOREDUCTIVE SURGERY | TOTAL LESION GLYCOLYSIS | OBSTETRICS & GYNECOLOGY | IMPACT | ONCOLOGY | RECURRENT | CARCINOMA | PROGRESSION | TUMOR VOLUME | Multivariate Analysis | Predictive Value of Tests | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasms, Glandular and Epithelial - metabolism | Tomography, X-Ray Computed - methods | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Multimodal Imaging | Neoplasms, Glandular and Epithelial - mortality | Biomarkers, Tumor - metabolism | Adult | Female | Ovarian Neoplasms - metabolism | Retrospective Studies | Neoplasms, Glandular and Epithelial - diagnosis | Radiopharmaceuticals | Neoplasm Recurrence, Local - metabolism | Ovarian Neoplasms - diagnosis | Neoplasm Recurrence, Local - therapy | Neoplasms, Glandular and Epithelial - therapy | Combined Modality Therapy | Neoplasm Recurrence, Local - diagnosis | Positron-Emission Tomography - methods | Tumor Burden | Survival Analysis | Carcinoma, Ovarian Epithelial | Glycolysis | Ovarian Neoplasms - therapy | Fluorodeoxyglucose F18 | ROC Curve | Aged | Medical research | Cancer patients | Relapse | PET imaging | Patient outcomes | Medicine, Experimental | Ovarian cancer | Diseases
Journal Article
Journal Article